In this issue:
- GNRHa + aromatase inhibitor/ LNG-IUD in endometrial carcinoma/ hyperplasia
- Letrozole + abemaciclib in oestrogen receptor-positive recurrent endometrial cancer
- Addition of avelumab to carboplatin + paclitaxel in advanced/recurrent endometrial cancer
- QOL with chemotherapy + pembrolizumab/placebo in persistent/recurrent/metastatic cervical cancer
- Chemo-radiation ± metformin in locally advanced cervical cancer
- Mirvetuximab soravtansine + bevacizumab in platinum-resistant ovarian cancer
- 7-year follow-up of olaparib in newly diagnosed advanced ovarian cancer + BRCA alteration
- Pafolacianine to enhance detection of macroscopic lesions in folate receptor-positive ovarian cancer
- Genetic prognostic markers in mucinous ovarian cancer vs. gastrointestinal cancer
- Avelumab + talazoparib in tumours with BRCA1/2 or ATM alterations
Please login below to download this issue (PDF)